Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 4/20 | 0.59 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.58 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.56 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | XDH | P47989 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29585950 | 1.00 | TSHR (0.59) | TSHRRAB9ALOXL2CREBBPALDH1A1 | |
| Acetone SCHEMBL27885920 | 0.91 | TSHR (0.64) | TSHRRAB9ALOXL2ALDH1A1CYP4F2 | |
| SCHEMBL34953 | 0.91 | TSHR (0.70) | TSHRRAB9ALOXL2ALDH1A1CYP4F2 | |
| SCHEMBL17348229 | 0.90 | CA12 (0.60) | TSHRRAB9ALOXL2ALDH1A1CYP4F2 | |
| Methyl Alcohol SCHEMBL28469619 | 0.89 | TSHR (0.67) | TSHRRAB9ALOXL2ALDH1A1CYP4F2 | |
| Ammonia Solution, Strong SCHEMBL28556515 | 0.89 | TSHR (0.67) | TSHRRAB9ALOXL2ALDH1A1CYP4F2 | |
| Potassium SCHEMBL30190417 | 0.89 | TSHR (0.67) | TSHRRAB9ALOXL2ALDH1A1CYP4F2 | |
| SCHEMBL29966404 | 0.89 | TSHR (0.67) | TSHRRAB9ALOXL2ALDH1A1CYP4F2 | |
| SCHEMBL10941453 | 0.89 | TSHR (0.67) | TSHRRAB9ALOXL2ALDH1A1CYP4F2 | |
| SCHEMBL8054504 | 0.89 | TSHR (0.67) | TSHRRAB9ALOXL2ALDH1A1CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 262 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118879796-A | Method for synthesizing methyl salicylate compound by taking biological enzyme as catalyst | 济南大学 | 2024-11-01 | — | — | CN | claimed |
| CN-118240886-A | Method for synthesizing ethyl salicylate compound by biological enzyme catalysis | 济南大学 | 2024-06-25 | — | — | CN | claimed |
| CN-109134222-B | Preparation method of 2-hydroxy isopropyl substituted acetophenone | 上海博栋化学科技有限公司 | 2022-01-21 | — | — | CN | claimed |
| CN-109134222-A | A kind of preparation method for the acetophenone that 2- hydroxyisopropyl replaces | 上海博栋化学科技有限公司 | 2019-01-04 | — | — | CN | claimed |
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2026-04-23 | — | — | US | disclosed |
| CN-115066428-B | Boric acid derivatives | 首药控股(北京)股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-119241504-A | Spiroindoline inhibitors of KIF18A | 沃拉斯查疗法公司 | 2025-01-03 | — | — | CN | disclosed |
| EP-3615525-B1 | PYRROLE DERIVATIVES AS PLK1 INHIBITORS | SENTINEL ONCOLOGY LTD (GB) | 2024-12-25 | — | — | EP | disclosed |
| US-20240351984-A1 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | US | disclosed |
| EP-3800186-B1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | MISSION THERAPEUTICS LTD (GB) | 2024-10-02 | — | — | EP | disclosed |
| CN-114450271-B | Ureas, amino and substituted heteroaryl compounds for Cbl-b inhibition | 纽力克斯治疗公司 | 2024-09-20 | — | — | CN | disclosed |
| WO-2024191268-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 현대약품 주식회사 | 2024-09-19 | — | — | WO | disclosed |
| WO-2001085723-A1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS (II) | JAMES BLACK FOUNDATION LIMITED (GB) | 2001-11-15 | — | — | WO | disclosed |
| EP-0509769-B1 | Heterocyclic amides having HLE inhibiting activity | ZENECA LTD (GB) | 1996-09-11 | — | — | EP | disclosed |
| US-5521179-A | Heterocyclic amides | ZENECA LIMITED (GB) | 1996-05-28 | — | — | US | disclosed |
| WO-1996004282-A1 | CARBAPENEM COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 1996-02-15 | — | — | WO | disclosed |
| EP-0509769-A2 | Heterocyclic amides having HLE inhibiting activity | ZENECA LIMITED (GB) | 1992-10-21 | — | — | EP | disclosed |
| EP-0083228-B1 | PHARMACEUTICALLY ACTIVE PHENYLCARBOXYLIC ACID DERIVATIVES | ICI AMERICAS INC. (US) | 1985-05-15 | — | — | EP | disclosed |
| US-4499299-A | Pharmaceutically active phenylcarboxylic acid derivatives | ICI AMERICAS INC. (US) | 1985-02-12 | — | — | US | disclosed |
| EP-0083228-A1 | Pharmaceutically active phenylcarboxylic acid derivatives | ICI AMERICAS INC. (US) | 1983-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240351984-A1 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | KIF18A, KIF18B, KIF2C | TSHR 4541/4885RAB9A 258/4885LOXL2 4140/4885 |
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | TSHR 34/4885RAB9A 665/4885LOXL2 2908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.